Darifenacin XR Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Darifenacin XR Availability in 2026

If your patients on Darifenacin XR (generic Enablex) are reporting difficulty filling their prescriptions, you're not alone in hearing this feedback. While Darifenacin XR is not currently listed on the FDA's drug shortage database, real-world availability issues persist due to market dynamics specific to this medication.

This briefing provides prescribers with the current availability picture, prescribing implications, cost and access considerations, and actionable tools to help your patients maintain continuity of care.

Timeline: How We Got Here

Darifenacin was FDA-approved in 2004 as Enablex, manufactured by Novartis. It was the first antimuscarinic marketed specifically for its M3 receptor selectivity in treating overactive bladder (OAB). Key developments:

• 2004: FDA approval of Enablex (darifenacin extended-release tablets) for OAB
• 2012-2013: Patent expiration and entry of generic competitors
• 2014-2018: Novartis gradually withdrew brand-name Enablex from the U.S. market
• 2019-present: Market served entirely by a limited number of generic manufacturers, including Par Pharmaceutical and Patriot Pharmaceuticals
• 2024-2026: Intermittent supply disruptions reported by patients, though no FDA-listed shortage

Prescribing Implications

Darifenacin's M3 selectivity was its primary differentiator at launch. In clinical practice, key considerations for prescribers include:

Pharmacological Profile

• Mechanism: Selective M3 muscarinic receptor antagonist
• Dosing: 7.5 mg once daily, may increase to 15 mg once daily after 2 weeks
• Dose adjustment: Maximum 7.5 mg/day with moderate hepatic impairment or concomitant potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, nefazodone)
• Metabolism: Primarily CYP3A4 and CYP2D6. Darifenacin is also a moderate CYP2D6 inhibitor, which has implications for co-prescribed medications metabolized by this pathway (flecainide, thioridazine, tricyclic antidepressants)

Clinical Positioning

Head-to-head studies have shown that antimuscarinics for OAB — including Darifenacin, Solifenacin, Tolterodine, and Oxybutynin — have comparable efficacy. The primary differences lie in side effect profiles and patient tolerance. Darifenacin's M3 selectivity may offer a theoretical advantage in reducing cognitive side effects compared to less selective agents, though clinical data supporting a meaningful difference has been mixed.

For patients currently stable on Darifenacin XR, the clinical rationale for maintaining their current regimen is strong — switching medications for OAB often requires dose titration and a new side-effect adjustment period. For more drug interaction details, see: Darifenacin XR Drug Interactions: What to Avoid.

Current Availability Picture

The availability of generic Darifenacin ER in 2026 can be characterized as follows:

• FDA shortage status: Not listed as of Q1 2026
• Real-world availability: Inconsistent. Many chain pharmacies do not routinely stock it due to low local demand
• Generic manufacturers: Limited to 2-3 active manufacturers, creating a narrow supply pipeline
• Distribution: Available through major wholesalers (McKesson, AmerisourceBergen, Cardinal Health) but not always in local pharmacy inventories
• Online/mail-order: More reliably available through mail-order and online pharmacies such as Cost Plus Drugs

The practical challenge for patients is not that Darifenacin ER is unavailable nationally, but that it often requires proactive effort to locate — calling multiple pharmacies, requesting special orders, or using online availability tools.

Cost and Access Considerations

Cost is an important factor when counseling patients on Darifenacin XR:

• Average retail price: $250-$330/month for 30 tablets (without insurance or coupons)
• With discount coupons: $26-$50/month through GoodRx, SingleCare, or similar programs
• Insurance coverage: Most commercial plans and Medicare Part D cover generic Darifenacin ER. Step therapy may be required (Oxybutynin or Tolterodine first). Prior authorization is occasionally required.
• Patient assistance: No manufacturer savings program available (brand discontinued). Patients may qualify for assistance through NeedyMeds, RxAssist, or pharmacy-specific discount programs.

For providers guiding patients on cost management: How to Help Patients Save Money on Darifenacin XR: A Provider's Guide.

Tools and Resources for Your Practice

Several tools can help you and your patients navigate Darifenacin XR availability challenges:

Medfinder for Providers

Medfinder offers a provider-facing platform that helps clinical teams locate pharmacies with medications in stock. You can direct patients to medfinder.com/providers or integrate the resource into your discharge and prescription workflows.

Prescribing Alternatives

When Darifenacin XR is genuinely unavailable and the patient cannot wait, the following alternatives are clinically reasonable:

• Solifenacin (Vesicare): Closest pharmacological match. M3-preferring antimuscarinic. 5 mg or 10 mg once daily. Generic widely available at $15-$40/month.
• Tolterodine ER (Detrol LA): Non-selective antimuscarinic. 2 mg or 4 mg once daily. First-line on most formularies. Generic at $10-$30/month.
• Mirabegron (Myrbetriq): Beta-3 agonist. Avoids anticholinergic burden. Appropriate for patients who experienced intolerable anticholinergic side effects. $300-$450/month brand, may be covered by insurance.
• Oxybutynin ER (Ditropan XL): Lowest cost option at $4-$15/month. Higher anticholinergic burden; use caution in elderly patients per AGS Beers Criteria.

For a patient-facing comparison: Alternatives to Darifenacin XR.

Looking Ahead

The overactive bladder treatment landscape continues to evolve. Key trends that may affect Darifenacin XR's role going forward:

• Generic market consolidation: Ongoing consolidation among generic manufacturers may further limit the number of Darifenacin ER producers
• Beta-3 agonist growth: Increasing utilization of Mirabegron and Vibegron, particularly in older adults, may reduce antimuscarinic prescribing overall
• Combination approaches: Growing evidence for antimuscarinic + beta-3 agonist combination therapy in refractory OAB
• Neuromodulation and Botox: Third-line interventions (sacral neuromodulation, onabotulinumtoxinA injection) continue to gain traction for refractory cases

Final Thoughts

Darifenacin XR remains a clinically valid and effective option for overactive bladder, but its limited generic manufacturing base creates real-world access challenges for patients. Providers can support their patients by proactively discussing availability, directing them to tools like Medfinder, and having a documented alternative plan in the patient's chart for when supply issues arise.

For the patient-facing version of this update, see: Darifenacin XR Shortage Update: What Patients Need to Know in 2026.